Catherine L Wall1, Richard B Gearry2, Andrew S Day1. 1. Department of Paediatrics, University of Otago Christchurch, Christchurch, New Zealand. 2. Department of Medicine, University of Otago Christchurch, Christchurch, New Zealand.
Abstract
BACKGROUND AND AIM: Enteral nutrition (EN) is not commonly used for the treatment of adults with active Crohn's disease (CD), despite patient interest in nutrition-based alternatives to corticosteroids and evidence of efficacy in paediatric CD. The aim of this study was to assess the impact of 2 different EN regimens on disease symptoms, nutrition and inflammatory markers in young adults with active CD. METHODS: A prospective non-randomized pilot study of adults aged 16-40 years with active CD on endoscopy or imaging was undertaken. Patients were sequentially recruited to use 2 weeks of exclusive EN (EEN) followed by either 6 weeks of EEN or partial EN (PEN) with usual diet. Assessments of disease symptoms, nutrition and inflammatory markers were undertaken at baseline and throughout the treatment. RESULTS: Thirty-eight patients with active disease were recruited. Thirty-two (84$) patients completed 2 weeks of EEN and had significant improvements in disease symptoms (p = 0.003), serum c-reactive protein (CRP; p = 0.005), insulin-like growth factor-1 (p = 0.006) and faecal calprotectin (FC; p = 0.028). During the following 6 weeks, 21 patients continued EEN (14 [67$] completed treatment) and 11 patients used PEN (9 [82$] completed treatment). Initial improvements in symptoms, CRP and nutrition markers were sustained over the next 6 weeks on both treatments. FC non-significantly increased in 5 out of 9 patients who used PEN and at week 8 FC was greater than 500 µg/g in 9 out of 14 and 7 out of 9 patients who used exclusive or PEN respectively. There was no significant difference in clinical outcomes between the 2 groups at week 8. CONCLUSION: Two weeks of EEN significantly improved disease symptoms, nutrition and inflammatory markers. Further treatment with exclusive or PEN maintained initial improvements.
BACKGROUND AND AIM: Enteral nutrition (EN) is not commonly used for the treatment of adults with active Crohn's disease (CD), despite patient interest in nutrition-based alternatives to corticosteroids and evidence of efficacy in paediatric CD. The aim of this study was to assess the impact of 2 different EN regimens on disease symptoms, nutrition and inflammatory markers in young adults with active CD. METHODS: A prospective non-randomized pilot study of adults aged 16-40 years with active CD on endoscopy or imaging was undertaken. Patients were sequentially recruited to use 2 weeks of exclusive EN (EEN) followed by either 6 weeks of EEN or partial EN (PEN) with usual diet. Assessments of disease symptoms, nutrition and inflammatory markers were undertaken at baseline and throughout the treatment. RESULTS: Thirty-eight patients with active disease were recruited. Thirty-two (84$) patients completed 2 weeks of EEN and had significant improvements in disease symptoms (p = 0.003), serum c-reactive protein (CRP; p = 0.005), insulin-like growth factor-1 (p = 0.006) and faecal calprotectin (FC; p = 0.028). During the following 6 weeks, 21 patients continued EEN (14 [67$] completed treatment) and 11 patients used PEN (9 [82$] completed treatment). Initial improvements in symptoms, CRP and nutrition markers were sustained over the next 6 weeks on both treatments. FC non-significantly increased in 5 out of 9 patients who used PEN and at week 8 FC was greater than 500 µg/g in 9 out of 14 and 7 out of 9 patients who used exclusive or PEN respectively. There was no significant difference in clinical outcomes between the 2 groups at week 8. CONCLUSION: Two weeks of EEN significantly improved disease symptoms, nutrition and inflammatory markers. Further treatment with exclusive or PEN maintained initial improvements.
Authors: A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis Journal: J Crohns Colitis Date: 2010-01-15 Impact factor: 9.071
Authors: F Goutorbe; M Goutte; R Minet-Quinard; A-L Boucher; B Pereira; G Bommelaer; A Buisson Journal: J Crohns Colitis Date: 2015-09-07 Impact factor: 9.071
Authors: Joanne L Grogan; David H Casson; Allyson Terry; Graham C Burdge; Wael El-Matary; A Mark Dalzell Journal: Inflamm Bowel Dis Date: 2011-03-18 Impact factor: 5.325
Authors: Andrew S Day; Kylie E Whitten; Daniel A Lemberg; Cathy Clarkson; Maribel Vitug-Sales; Reuben Jackson; Tim D Bohane Journal: J Gastroenterol Hepatol Date: 2006-10 Impact factor: 4.029
Authors: K Frivolt; T Schwerd; K J Werkstetter; A Schwarzer; S B Schatz; P Bufler; S Koletzko Journal: Aliment Pharmacol Ther Date: 2014-04-30 Impact factor: 8.171
Authors: V M Navas-López; J Blasco-Alonso; S Lacasa Maseri; F Girón Fernández-Crehuet; M J Serrano Nieto; M I Vicioso Recio; C Sierra Salinas Journal: An Pediatr (Barc) Date: 2014-04-02 Impact factor: 1.500
Authors: Jason C O'Connor; Robert H McCusker; Klemen Strle; Rodney W Johnson; Robert Dantzer; Keith W Kelley Journal: Cell Immunol Date: 2008-03-05 Impact factor: 4.868
Authors: H Malchow; H J Steinhardt; H Lorenz-Meyer; W D Strohm; S Rasmussen; H Sommer; S Jarnum; J W Brandes; H Leonhardt; K Ewe Journal: Scand J Gastroenterol Date: 1990-03 Impact factor: 2.423
Authors: Congqiao Jiang; Pingsheng Zhu; Yi Shi; Wujun Xiang; Sitang Ge; Zongbing Zhang; Lugen Zuo Journal: Nan Fang Yi Ke Da Xue Xue Bao Date: 2019-07-30
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059